Ultrasound Workspace (UWS 6.0) vs AVIEW

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
VS
by Coreline Soft Co.

AI Verdict

Tool A is specifically designed for enhancing echocardiography workflows, providing AI-powered measurements and analysis for cardiovascular assessment using ultrasound images. In contrast, Tool B focuses on AI-driven detection and monitoring of lung pathologies and coronary artery calcification from CT scans. While both tools operate within the broader radiology and cardiology domains, their distinct imaging modalities and specific clinical applications make them complementary rather than direct competitors.

Choose Ultrasound Workspace (UWS 6.0) if…

Choose Philips Ultrasound Workspace (UWS 6.0) if your cardiology department requires a dedicated, vendor-neutral solution for advanced echocardiography analysis and reporting. This tool excels at providing highly reproducible, AI-powered automated measurements for various cardiac structures and functions, streamlining complex echo workflows and enhancing diagnostic confidence across different ultrasound systems.

View Ultrasound Workspace (UWS 6.0) →

Choose AVIEW if…

Choose Coreline Soft's AVIEW if your radiology practice needs a comprehensive AI platform for the early detection, diagnosis, and monitoring of multiple conditions from CT scans. This solution is particularly well-suited for screening programs involving lung cancer (nodule detection and characterization), COPD quantification, and cardiovascular risk assessment through automated coronary artery calcium scoring, with robust follow-up features.

View AVIEW →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Ultrasound Workspace (UWS 6.0) AVIEW
Pricing Unknown Subscription; one-off payment
Deployment On-premise (single-seat workstation, multi-seat server) Cloud-based; Hybrid solution; Locally on dedicated hardware; Locally virtualized (virtual machine, Docker)
FDA Status Cleared AI-estimated Cleared AI-estimated
HIPAA Yes AI-estimated Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

AVIEW

While both tools aim to streamline workflows and integrate with existing systems, Tool B (AVIEW) explicitly highlights an 'optimized user interface (UI) and user experience (UX)'. Furthermore, clinical validation for AVIEW shows radiologists achieving '89% faster case throughput and 60% reduction in interpretation time', providing a strong quantitative measure of its positive impact on workflow efficiency.

Clinical Value

AVIEW

Both tools offer significant clinical value in their respective domains. However, Tool B (AVIEW) provides a broader diagnostic scope by addressing multiple high-fatality illnesses (lung cancer, COPD, coronary artery calcification, ILD) from a single CT scan. It also boasts strong clinical validation, demonstrating a 'lower likelihood of misidentifying nodules larger than 100 mmu00b3 compared with human radiologists' and adoption in national lung cancer screening programs across Europe.

Pricing & Value

AVIEW

Tool B (AVIEW) offers greater transparency regarding its pricing model, stating options for 'subscription' or 'one-off payment' based on 'number of installations' and 'number of users'. In contrast, Tool A (UWS 6.0) only provides a generic 'contact for pricing' statement, offering less initial clarity to potential buyers.

Enterprise Readiness

AVIEW

Both tools are FDA-cleared, HIPAA compliant, and offer integration with PACS/EMR systems. However, Tool B (AVIEW) demonstrates superior enterprise readiness through its broader deployment options (cloud, hybrid, local, virtualized) and extensive real-world adoption, having processed 'over 2.5 million cases across 19 countries'. It also explicitly mentions validation against interoperability standards like IHE and FHIR.

Innovation

AVIEW

While Tool A (UWS 6.0) innovates with comprehensive, vendor-neutral echocardiography analysis and advanced 3D measurements, Tool B (AVIEW) showcases a more expansive and forward-thinking approach. AVIEW 2.0 represents a 'paradigm shift from task-specific tools to an integrated diagnostic ecosystem' by seamlessly combining multiple thoracic pathologies. Furthermore, Coreline Soft is exploring 'opportunistic screening' for conditions like bone density from existing CT scans, indicating a broader innovative trajectory.

Support & Docs

Ultrasound Workspace (UWS 6.0)

Tool A (UWS 6.0) benefits from Philips' 'extensive global infrastructure,' which includes 'comprehensive training and education programs through the Philips Learning Center and TOMTEC ACADEMY'. This suggests a more robust and established support ecosystem with tailored support and regular software upgrades. While Tool B engages in educational activities like webinars, it does not detail a comparable comprehensive support structure.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Ultrasound Workspace (UWS 6.0) AVIEW
Name Ultrasound Workspace (UWS 6.0) AVIEW
Company Philips Ultrasound Coreline Soft Co.
Description Philips Ultrasound Workspace (UWS 6.0) is a holistic, scalable, AI-powered cardiovascular viewing, analysis, and reporting system designed to streamline echocardiography workflows, enhance diagnostic confidence, and improve reproducibility through vendor-neutral data analysis and flexible deployment. Coreline Soft's AVIEW AI platform offers comprehensive solutions for the early detection, diagnosis, and monitoring of lung cancer, COPD, and coronary artery calcification from CT scans, enhancing diagnostic precision and streamlining radiology workflows.
Categories Cardiology AI, Radiology & Imaging AI Cardiology AI, Oncology AI, Radiology & Imaging AI
Specialties Cardiology, Critical Care, Radiology Cardiology, Pulmonology, Radiology
Key Features (Examples) AI-powered automated measurements (e.g., Auto Measure, AutoStrain LV, 3D Auto RV, 3D Auto MV, 3D Auto TV, 3D Auto CFQ); Vendor-neutral and multi-vendor data analysis for standardization; Comprehensive cardiovascular software solutions (review, image analysis, reporting, image management) AI-powered lung nodule detection and characterization (size, volume, type, location, Lung-RADS score); Emphysema quantification and low attenuation area (LAA) analysis; Coronary artery calcium (CAC) scoring (Agatston, volume, mass score, risk stratification)

Videos

Demos, reviews, and walkthroughs featuring Ultrasound Workspace (UWS 6.0) and AVIEW.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Philips Ultrasound Workspace (UWS 6.0) is designed for cardiovascular viewing, analysis, and reporting, specifically streamlining echocardiography workflows. AVIEW, on the other hand, offers solutions for the early detection, diagnosis, and monitoring of lung cancer, COPD, and coronary artery calcification from CT scans.
UWS 6.0 features AI-powered automated measurements for echocardiography, such as Auto Measure, AutoStrain LV, and 3D Auto RV, MV, TV, and CFQ. AVIEW's AI capabilities include lung nodule detection and characterization, emphysema quantification, coronary artery calcium (CAC) scoring, and automated segmentation of lung structures and coronary arteries.
Philips Ultrasound Workspace 6.0 explicitly highlights vendor-neutral and multi-vendor data analysis for standardization. While AVIEW integrates with PACS/RIS/CIS, its description does not explicitly state vendor-neutral data analysis as a key feature for multi-vendor CT data.
Philips Ultrasound Workspace 6.0 offers integration with existing PACS and EMR systems. AVIEW also provides workflow automation and integration with PACS, RIS, and CIS.
AI Tool Finder
AI-powered search. Results may not be comprehensive.